Table 1.
Summary of individual studies included in this analysisa
| Sponsor | Study number | Regimens | Study size | Endpoint |
|---|---|---|---|---|
| NABTC | 97-01 | Temozolomide + carmustine | 36 | PFS6 |
| 97-05 | Thymidine + carboplatin | 45 | Response | |
| 98-01 | Irinotecan | 64 | PFS6 | |
| 98-03 | Temozolomide + 13-cis-retinoic acid | 87 | PFS6 | |
| 99-01 | Zarnestra | 92 | PFS6 | |
| 99-04 | Temozolomide + thalidomide | 44 | PFS6 | |
| 99-05 | Fenretinide | 42 | PFS6 | |
| 99-07 | Temozolomide + irinotecan | 35 | PFS6 | |
| 99-08 | Imatinib | 42 | PFS6 | |
| 00-01 | Gefitinib | 50 | PFS6 | |
| 01-01 | Temsirolimus | 41 | PFS6 | |
| 01-03 | Erlotinib | 18 | PFS6 | |
| NCCTG | 797251 | Etoposide vs teniposide | 86 | Response |
| 847251 | Fludarabine | 7 | Response | |
| 867202 | Interferon-α + difluoromethylornithine | 22 | Response | |
| 867253 | Interferon-α + carmustine | 17 | Response | |
| 867254 | Etoposide + cisplatin | 16 | Response | |
| 887251 | Ifosfamide + sodium 2-mercaptoethane sulfonate | 14 | Response | |
| 897251 | 5-Fluorouracil + leucovorin | 28 | Response | |
| 897252 | Amonafide | 20 | Response | |
| 917251 | Mechlorethamine + vincristine + procarbazine | 45 | Response | |
| 927251 | Topotecan | 29 | Response | |
| 937251 | 2-Chlorodeoxyadenosine | 9 | Response | |
| 957253 | Dacarbazine | 29 | Response | |
| 967251 | Irinotecan | 53 | Response | |
| 987254 | Pyrazoloacridine + carboplatin | 34 | Response | |
| N997B | Temsirolimus | 60 | PFS6 |
Abbreviations: NABTC, North American Brain Tumor Consortium; NCCTG, North Central Cancer Treatment Group; PFS6, progression-free survival rate at 6 months.
aAll patients on these studies or their designated surrogates signed an approved institutional review board consent form.